Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo-controlled study

被引：0
|
作者：
Sanchez, R
McQuade, R
Marcus, R
Carson, W
Rollin, L
Iwamoto, T
Stock, E
机构：
[1] Bristol Myers Squibb, Pharmaceut Res Inst, Wallingford, CT 06492 USA
[2] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT 06492 USA
[4] Otsuka Pharmaceut Co Ltd, Tokyo, Japan
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S511 / S512
页数：2
相关论文
共 50 条
  • [1] Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo-controlled study
    Sanchez, R
    Rollin, L
    Kostic, D
    Iwamoto, T
    McQuade, R
    Keck, P
    BIPOLAR DISORDERS, 2005, 7 : 94 - 94
  • [2] Aripiprazole for relapse prevention in bipolar disorder: A 26-week placebo-controlled study
    Keck, PE
    Carlson, B
    Rollin, L
    McQuade, R
    Gutierrez-Esteinou, R
    Pikalov, A
    Sanchez, R
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 129S - 129S
  • [3] Aripiprazole for relapse prevention in bipolar disorder: A 26-week placebo controlled study
    McQuade, R
    Sanchez, R
    Marcus, R
    Carson, W
    Rollin, L
    Iwamoto, T
    Stock, E
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S161 - S161
  • [4] Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
    Pigott, TA
    Carson, WH
    Saha, AR
    Torbeyns, AF
    Stock, EG
    Ingenito, GG
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (09) : 1048 - 1056
  • [5] Aripiprazole for relapse prevention in bipolar disorder: A 100-week, double-btind, placebo-controlled study
    McIntyre, Roger S.
    Kennedy, Sidney H.
    Carlson, Berit
    Carson, William
    McQuade, Robert
    Rollin, Linda
    Marcus, Ronald
    Sanchez, Raymond
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S229 - S229
  • [6] Aripiprazole maintenance therapy in bipolar disorder: a placebo-controlled, 74-week extension of a 26-week study (CN138-010)
    Marcus, R. N.
    Keck, P. E.
    Calabrese, J. R.
    McIntyre, R. S.
    Momah, C.
    Carson, W. H.
    McQuade, R. D.
    Carlson, B. X.
    Eudicone, J.
    Sanchez, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S453 - S454
  • [7] Maintenance therapy of aripiprazole vs. placebo in bipolar I disorder: a double-blind, placebo-controlled, 74-week extension of a 26-week study
    McIntyre, R. S.
    Keck, P.
    Calabrese, J.
    Momah, C.
    Carson, W.
    McQuade, R.
    Marcus, R.
    Carlson, B. X.
    Eudicone, J.
    Sanchez, R.
    BIPOLAR DISORDERS, 2007, 9 : 76 - 76
  • [8] A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder
    Keck, Paul E., Jr.
    Calabrese, Joseph R.
    McQuade, Robert D.
    Carson, William H.
    Carlson, Berit X.
    Rollin, Linda M.
    Marcus, Ronald N.
    Sanchez, Raymond
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (04) : 626 - 637
  • [9] Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study
    Findling, Robert L.
    Correll, Christoph U.
    Nyilas, Margaretta
    Forbes, Robert A.
    McQuade, Robert D.
    Jin, Na
    Ivanova, Svetlana
    Mankoski, Raymond
    Carson, William H.
    Carlson, Gabrielle A.
    BIPOLAR DISORDERS, 2013, 15 (02) : 138 - 149
  • [10] The long-term effects of aripiprazole on the lepid profiles of patients with schizophrenia in a 26-week placebo-controlled trial
    Meyer, J. M.
    Formal, A.
    Kaplita, S.
    Forbes, A.
    Grossman, F.
    Pikalov, A.
    Marcus, R. N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S157 - S157
12345